Improving enzyme replacement therapies using targeted fluorination
Official title: Targeted fluorination for improved pharmacology of enzyme replacement therapies
Funded at Halide Biologics, INC. · NIH-11007701 · Data updated 2026-11-12
This study is looking at a new way to make enzyme replacement therapies better for people with metabolic disorders by using a special technique to improve the proteins in the treatments, which could help you feel healthier.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Halide Biologics, INC. NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,873 |
| NIH project number | 1R43HD116671-01 |
| Project ID | NIH-11007701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with inborn errors of metabolism that require enzyme replacement therapy.
✕Less likely to help
Patients who do not have metabolic disorders or those who are not candidates for enzyme replacement therapy may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of enzyme replacement therapies (ERTs) by using a technique called targeted fluorination. By substituting specific amino acids in recombinant proteins with fluorinated analogs, the researchers aim to improve the stability and efficacy of these treatments. Patients with metabolic disorders that require ERT may benefit from these improved therapies, which could lead to better health outcomes. The project will compare the performance of these novel therapies against current standard treatments to assess their potential advantages.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier-to-administer enzyme replacement therapies for patients with metabolic disorders.
How similar studies have gone: Previous research has shown promise in enhancing protein therapeutics through chemical modifications, indicating that this approach may yield beneficial results.
Where this research is happening
-
Halide Biologics, INC.
Iowa City, United States Active
Researchers
- Principal investigator: Infield, Daniel T — Halide Biologics, INC.
- Study coordinator: Infield, Daniel T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.